← Back to Clinical Trials
Recruiting NCT06134791

NCT06134791 Differences in Characteristics of Headache Patients With a Positive or Negative FRT: a Cross-sectional Comparison.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06134791
Status Recruiting
Phase
Sponsor University Ghent
Condition Headache
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2023-07-01
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
No intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2023-07-01 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

An observational study will be conducted to evaluate the differences in headache characteristics between a subgroup of cervicogenic headache patients with a positive and negative flexion-rotation test at the C1-C2 level. Differences may guide future treatment allocation and the use of more individualized treatment options.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of cervicogenic headache according to the ICHD-3 criteria: A. Any headache fulfilling criterion C B. Clinical and/or imaging evidence1 of a disorder or lesion within the cervical spine or soft tissues of the neck, known to be able to cause headache2 C. Evidence of causation demonstrated by at least two of the following: * headache has developed in temporal relation to the onset of the cervical disorder or appearance of the lesion * headache has significantly improved or resolved in parallel with improvement in or resolution of the cervical disorder or lesion * cervical range of motion is reduced, and headache is made significantly worse by provocative manœuvres * headache is abolished following diagnostic blockade of a cervical structure or its nerve supply D. Not better accounted for by another ICHD-3 diagnosis Age: 18+ years Headache for at least 1 day/week for at least 3 months Limited mobility of the neck NPRS \> 3/10 Exclusion Criteria: * Primary headache forms: migraine, TTH * Other secondary headaches that do not comply with the ICDH-3 criteria for CH * Whiplash or other traumatic incident in the past * Pregnancy or given birth in the last year * Previous head, neck or shoulder surgery * Cervical radiculopathy complaints * Receiving other treatments for headache or neck pain (physical therapy/ostheopathy/chiropraxie...) in the previous month

Contact & Investigator

Central Contact

Barbara Cagnie, Prof. dr.

✉ Barbara.Cagnie@Ugent.be

📞 +32 9 332 52 6

Principal Investigator

Barbara Cagnie, Prof. dr.

PRINCIPAL INVESTIGATOR

University Ghent

Frequently Asked Questions

Who can join the NCT06134791 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Headache. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06134791 currently recruiting?

Yes, NCT06134791 is actively recruiting participants. Contact the research team at Barbara.Cagnie@Ugent.be for enrollment information.

Where is the NCT06134791 trial being conducted?

This trial is being conducted at Ghent, Belgium.

Who is sponsoring the NCT06134791 clinical trial?

NCT06134791 is sponsored by University Ghent. The principal investigator is Barbara Cagnie, Prof. dr. at University Ghent. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology